Navigation Links
Wound Management Technologies, Inc. Announces Conference Plans and Clinical Data Presentation at Leading Diabetic Foot Conference
Date:3/15/2010

,'ExternalLink');" target='_blank' href="http://www.Celleraterx.com">www.Celleraterx.com .

About Wound Management Technologies, Inc.

Wound Management Technologies Inc's primary focus is the distribution of its unique, patented collagen product, CellerateRX®, in the $3.2B worldwide advanced wound care market, a market that is growing due to aging populations and the increase of diabetes.  Over the past 2 years WMT has focused on developing evidenced-based studies on CellerateRX and gaining physician awareness by participation in key industry conferences. Now WMT is focused on expanding sales through partnerships and contracted independent representatives. WMT has other advanced biotech products in development for bone wax, bone void fillers and shingles pain reduction as well as a subsidiary focused on eHealth technology for secure healthcare data collaboration and storage.  More information can be found on the company's websites: www.wmgtech.com, www.CellerateRX.com , and

SOURCE Wound Management Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Healing Wounds and Hearts: Warrior Weekend Helps Soldiers and Marines Relax and Recover
2. A novel in vitro model for light-induced wound healing
3. Wounded Soldier Who Received Historic Cell Transplant Gets Standing Ovation at Diabetes Research Institute Benefit
4. Wound-Healing Maggots Succumb to Deadly Bacteria
5. Wounded Warrior Project and Operation Touchdown 2010 Join Forces for Super Bowl XLIV
6. Wound treatment wins commercialization funds
7. Avery Dennison Innovates in Consumer Wound Care
8. LCA-Vision Joins Forces With the Wounded Warrior Project to Give the Gift of Enhanced Vision to Wounded American Heroes
9. Wounded Vets, CAREER Counselors Gather in Washington as Obama Announces Afghanistan Troop Buildup
10. Wounded Warrior Project (WWP) Applauds the Senate for Passing Crucial Family Caregiver Legislation
11. Wake Pharma US, Inc. Announces the Appointment of Kim Eldridge as Coordinator & Clinical Wound Specialist Educator
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... The first-ever successful isolation and culture of ... been achieved by NFCR-supported scientist Daniel Haber, M.D., Ph.D., ... an important milestone on the road to individualized cancer ... for each patient. , “Tumors evolve in response ... genetic features that make them resistant to drugs. If ...
(Date:7/24/2014)... cancer involves exposing the patient or their tumor more ... X-rays. The radiation damages the cancer cells irreparably. Unfortunately, ... the skin over the site of the tumor, which ... and even skin cancer. As such finding ways to ... in the International Journal of Low Radiation, Faruck Lukmanul ...
(Date:7/24/2014)... Researchers have uncovered a way the malaria parasite ... at Washington University School of Medicine in St. ... including bacterial infections and tuberculosis. , The study ... , Many organisms, including the parasite that causes ... which play multiple roles in keeping organisms healthy, ...
(Date:7/24/2014)... July 24, 2014 July 22, ... in sealant and anesthesia reversal products to National ... help save young smiles. The donation of over ... Oraverse® was distributed to America’s ToothFairy Affiliate clinical ... vital oral health services. The America’s ToothFairy Affiliate ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 Recently, Stwd.co.uk, a ... enriched its product line by adding many new designs of ... All outfits in the new collection come with big discounts. ... launching a special offer on all these fashionable items. They ... example, a pink V-neck strapless beading prom dress was previously ...
Breaking Medicine News(10 mins):Health News:New Blood Test Advances Individualized Cancer Therapy and Cuts Down on Need for Painful Biopsies 2Health News:Natural products from plants protect skin during cancer radiotherapy 2Health News:One route to malaria drug resistance found 2Health News:One route to malaria drug resistance found 3Health News:Septodont Donation Helps Children in Need 2Health News:Cheap Wedding Dresses Are Offered by Stwd.co.uk at Low Prices 2
... , , , SOUTH SAN FRANCISCO, Calif., ... scientific presentations at the International Society on Thrombosis and ... its investigational antiplatelet drug elinogrel, a P2Y(12) ADP receptor ... oral Factor Xa inhibitor anticoagulant antidote in pre-clinical development, ...
... most people sidelined for long, study shows , FRIDAY, July ... full participation in sports or activity within six months of ... , U.S. researchers examined questionnaires filled out by 165 patients, ... performed by a single surgeon between July 1, 2004 and ...
... though, that screenings remain vital , THURSDAY, July 9 (HealthDay ... a screening mammogram is unlikely to ever cause a problem, ... overdiagnosis rate of 35 percent came from an examination of ... researchers and published online Thursday in BMJ . , ...
... (NYSE: WPI ), a leading specialty pharmaceutical company, ... quarter 2009 financial results on Wednesday, July 29, 2009 prior ... Company will also host a conference call and webcast at ... discuss its financial results and provide an update on the ...
... INDIANAPOLIS, July 10 Eli Lilly and Company ... this, its 35th year of support for the Indiana Black Expo (IBE) ... and a presence at the IN Shape Indiana Black ... stay healthy in these uncertain economic times. , , An example ...
... PALM CITY, Fla., July 10 Connectyx Technologies Holdings Group, ... Company is looking to establish itself as the market leader ... by Connectyx CEO, Ronn Schuman during yesterday,s Nationwide Teleconference. ... a goal to reach 1.2 million members by the end ...
Cached Medicine News:Health News:Portola Pharmaceuticals Announces Several Scientific Presentations at International Society on Thrombosis and Haemostasis XII Congress 2Health News:Portola Pharmaceuticals Announces Several Scientific Presentations at International Society on Thrombosis and Haemostasis XII Congress 3Health News:Shoulder Surgery Helps Athletes Get Back in the Game 2Health News:More Mammograms May Mean More 'Harmless' Cancers 2Health News:Watson to Host Second Quarter 2009 Earnings Conference Call and Webcast 2Health News:Lilly Celebrates Its 35th Year as a Supporter of the Indiana Black Expo 2Health News:Lilly Celebrates Its 35th Year as a Supporter of the Indiana Black Expo 3Health News:Connectyx Looks to Establish Market Leadership with MedSync and MedFlash Product Line As Stated During Nationwide Teleconference 2Health News:Connectyx Looks to Establish Market Leadership with MedSync and MedFlash Product Line As Stated During Nationwide Teleconference 3
(Date:7/24/2014)... July 24, 2014 Celsion Corporation (NASDAQ: ... data from its ongoing open-label Phase 2 DIGNITY ... Cancer (RCWBC).  The trial is designed to enroll ... is evaluating ThermoDox in combination with mild hyperthermia. ... eligible for evaluation of efficacy.  Based on data ...
(Date:7/24/2014)... HIGHLIGHTS:Q2 2014 Results (all percentage changes ... sales increased 3% to $701 million.  Sales grew organically by ... percentage point to sales growth. , By business unit, ... and 1% in SAFC Commercial. , Reported diluted EPS ... of 13%.  Adjusted diluted EPS in Q2 2014 was also ...
(Date:7/24/2014)... and VANCOUVER, British Columbia , ... OGXI ) announced today that the Company,s ... Thursday, August 7, 2014, and that the Company will ... p.m. ET that afternoon. Management will provide an overview ... general business update. To access the ...
Breaking Medicine Technology:Celsion Announces Positive Interim Data Update from its Phase 2 DIGNITY Study in Breast Cancer 2Celsion Announces Positive Interim Data Update from its Phase 2 DIGNITY Study in Breast Cancer 3Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 2Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 3Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 4Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 5Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 6Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 7Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 8Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 9Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 10Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 11Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 12Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 13Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 14Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 15Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 16Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 17Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 18Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 19Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 20Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 21Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 22OncoGenex to Report Financial Results for Second Quarter 2014 on August 7, 2014 2
... 26 Bristol-Myers Squibb,Company (NYSE: BMY ) ... in which treatment of antiviral-naive adult chronic hepatitis ... viral,load reduction than adefovir at 96 weeks -- ... viral load to undetectable,levels is a measure of ...
... ... C Clarification of Oncogenic Pathways Aids ... Benefit in Liver Transplantation, MILAN, April 26 , - Systems Biology Helps ... of the European,Association for the Study of the Liver (EASL), experts reported advances in,basic ...
Cached Medicine Technology:BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients 2BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients 3BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients 4BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients 5BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients 6BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients 7Basic Science Discoveries Yield Progress in Hepatology 2Basic Science Discoveries Yield Progress in Hepatology 3Basic Science Discoveries Yield Progress in Hepatology 4
Full Handle Laseredge Implant Blade Knife, 5.2 mm angled bevel up. Blade dimension: 16.5 mm x 5.2 mm x 4.2 mm x 1.6 mm....
Full Handle Laseredge Implant Blade Knife, 4.0 mm angled bevel up. Blade dimension: 15.2 mm x 4.0 mm x 3.0 mm x 1.6 mm....
Full Handle Laseredge Crescent Blade Knife, angled bevel down. Blade tip dimension: 12.7 mm x 2.0 mm x 3.8 mm....
Full Handle Laseredge Crescent Blade Knife, straight. Blade tip dimension: 12.7 mm x 2.0 mm x 3.8 mm....
Medicine Products: